Education
About Us
Working with TipRanks
Follow Us
Mind Medicine Inc. (MNMD)
:MNMD
MNMD Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MNMD Stock 12 Month Forecast
Average Price Target
$35.00
▲(208.64% Upside)
| Highest Price Target$55.00 | Average Price Target$35.00 | Lowest Price Target$25.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Needham
$28
Buy
146.91%
Upside
Reiterated
11/07/25
Mind Medicine's Accelerated Phase 3 Trials and Strong Financial Position Signal Promising FutureWe expect MNMD to trade positively following its earnings update after the close on Thursday. The main positive update from the earnings call was that the enrollment for the EMERGE Ph 3 MDD study is progressing faster than expected, thus, its readout is now expected in mid-2026 (vs 2H26 previously). Further, management announced its plans to initiate the second Ph 3 study in and provided details on its trial design (inside). 3 GAD studies continue to enroll and remain on track for the VOYAGE study to readout in 1H26 and the PANORAMA study to readout in 2H26. With the recent ~$259M financing extends the cash runway into 2028, and puts Mindmed in a strong financial position to execute on its pipeline. We update our model for the quarter and reiterate our Buy rating.
Canaccord Genuity
$16→$25
Buy
120.46%
Upside
Reiterated
11/07/25
LifeSci Capital
$32
Buy
182.19%
Upside
Reiterated
11/07/25
RBC Capital
$20
Buy
76.37%
Upside
Reiterated
11/06/25
H.C. Wainwright
$35→$55
Buy
385.01%
Upside
Reiterated
09/23/25
Roth MKM
$36
Buy
217.46%
Upside
Reiterated
08/04/25
Maxim Group
$18
Buy
58.73%
Upside
Reiterated
08/04/25
Chardan Capital
$20
Buy
76.37%
Upside
Reiterated
08/01/25
Leerink Partners
$20
Buy
76.37%
Upside
Reiterated
08/01/25
Evercore ISI
$23
Buy
102.82%
Upside
Reiterated
07/11/25
Robert W. Baird
$27→$16
Buy
41.09%
Upside
Reiterated
03/07/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Needham
$28
Buy
146.91%
Upside
Reiterated
11/07/25
Mind Medicine's Accelerated Phase 3 Trials and Strong Financial Position Signal Promising FutureWe expect MNMD to trade positively following its earnings update after the close on Thursday. The main positive update from the earnings call was that the enrollment for the EMERGE Ph 3 MDD study is progressing faster than expected, thus, its readout is now expected in mid-2026 (vs 2H26 previously). Further, management announced its plans to initiate the second Ph 3 study in and provided details on its trial design (inside). 3 GAD studies continue to enroll and remain on track for the VOYAGE study to readout in 1H26 and the PANORAMA study to readout in 2H26. With the recent ~$259M financing extends the cash runway into 2028, and puts Mindmed in a strong financial position to execute on its pipeline. We update our model for the quarter and reiterate our Buy rating.
Canaccord Genuity
$16→$25
Buy
120.46%
Upside
Reiterated
11/07/25
LifeSci Capital
$32
Buy
182.19%
Upside
Reiterated
11/07/25
RBC Capital
$20
Buy
76.37%
Upside
Reiterated
11/06/25
H.C. Wainwright
$35→$55
Buy
385.01%
Upside
Reiterated
09/23/25
Roth MKM
$36
Buy
217.46%
Upside
Reiterated
08/04/25
Maxim Group
$18
Buy
58.73%
Upside
Reiterated
08/04/25
Chardan Capital
$20
Buy
76.37%
Upside
Reiterated
08/01/25
Leerink Partners
$20
Buy
76.37%
Upside
Reiterated
08/01/25
Evercore ISI
$23
Buy
102.82%
Upside
Reiterated
07/11/25
Robert W. Baird
$27→$16
Buy
41.09%
Upside
Reiterated
03/07/25
Best Analysts Covering Mind Medicine
1 Month
xxx
Success Rate
4/8 ratings generated profit
Average Return
+8.10%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +8.10% per trade.
3 Months
xxx
Success Rate
6/8 ratings generated profit
Average Return
+22.49%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +22.49% per trade.
1 Year
Success Rate
18/20 ratings generated profit
Average Return
+80.19%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +80.19% per trade.
2 Years
xxx
Success Rate
12/12 ratings generated profit
Average Return
+154.50%
reiterated a xxx
rating 3 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +154.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MNMD Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
8
11
12
13
6
Buy
1
0
0
0
0
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
11
12
13
6
Each month's total comprises the sum of three months' worth of ratings.
MNMD Financial Forecast
MNMD Stock Forecast FAQ
What is MNMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Mind Medicine Inc.’s 12-month average price target is 35.00.
What is MNMD’s upside potential, based on the analysts’ average price target?
Mind Medicine Inc. has 208.64% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MNMD a Buy, Sell or Hold?
Mind Medicine Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Mind Medicine Inc.’s price target?
The average price target for Mind Medicine Inc. is 35.00. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $55.00 ,the lowest forecast is $25.00. The average price target represents 208.64% Increase from the current price of $11.34.
The highest analyst price target is $55.00 ,the lowest forecast is $25.00. The average price target represents 208.64% Increase from the current price of $11.34.
What do analysts say about Mind Medicine Inc.?
Mind Medicine Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of MNMD?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.